Phaseline

Companies › Vor Biopharma

Vor Biopharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Neurology, Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Telitacicept–Phase 3Generalized Myasthenia Gravis; Primary Sjogren's DiseaseMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06456580TelitaciceptPhase 3Generalized Myasthenia GravisNeurologyMar 2027
NCT07404865TelitaciceptPhase 3Primary Sjogren's DiseaseImmunologyDec 2028

From the company's SEC filings

Cash and short-term investments of $482m on 2026-09-30; operating cash outflow about $129m a year; runway about 45 months at that burn, to Jun 2030; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Zenas BioPharma (USA) Chengdu Kangnuoxing Biopharma Dianthus Therapeutics Q32 Bio Keros Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.